Leading stem cell and exosome therapy research blog by Cell La Vie, Bangkok. Clinical insights, cost breakdowns, and regenerative treatment guides.
A 2026 Phase 1 trial showed that MSC-derived exosomes injected into the ear were safe and improved hearing in patients with sudden sensorineural hearing loss. Here’s what the breakthrough means and when it could be available.
Read More »Stem cell therapy prices range from $2,000 to $100,000 depending on where you go. Here’s what actually drives the cost, what’s included, and how Thailand compares to the US, Australia, and Europe in 2026.
Read More »MSC therapy is offering new hope for IBD patients who don’t respond to conventional biologics. Here’s what the 2026 clinical data shows.
Read More »Kaempferol-modified MSC extracellular vesicles suppress ADAM10 and restore UV-damaged collagen. This is the future of anti-aging skin repair.
Read More »A 2025 clinical trial reports the first-ever strength improvement in ALS patients using intranasally delivered MSC exosomes — zero adverse events across 32 treatments.
Read More »PRP has its limits. For serious tendon and ligament injuries, stem cells are showing results PRP cannot match.
Read More »A June 2026 study shows that senolytic preconditioning dramatically improves MSC efficacy by removing the SASP factors that suppress tissue repair. Plus: AAT-MSCs reverse diabetes via immune reprogramming, and a phase III MSC trial for meniscal repair reaches completion.
Read More »A 2026 real-world study followed 120 refractory lupus nephritis patients treated with UC-MSCs. Cumulative renal response reached 56.7% at 12 months with low relapse rates and zero severe adverse events. Here’s what clinicians need to know.
Read More »A 36-month clinical trial showed zero adverse events and 57% pain reduction when stem cells were injected into torn rotator cuffs. Here’s what weekend warriors and recreational athletes need to know about MSC therapy for sports injuries.
Read More »Every workout floods your bloodstream with stem cells — your body’s own repair crew. Learn how exercise mobilizes regenerative cells and why it matters for aging and healing.
Read More »The MERIT phase 1 trial published in Cell Reports Medicine shows that intravenous UC-MSC therapy is safe in subacute ischemic stroke, with early NIHSS improvement signals. Here’s what clinicians need to know.
Read More »